S&T Bank PA Lowers Position in AbbVie Inc. $ABBV

S&T Bank PA trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 8.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 37,712 shares of the company’s stock after selling 3,264 shares during the period. AbbVie comprises approximately 2.1% of S&T Bank PA’s portfolio, making the stock its 12th biggest holding. S&T Bank PA’s holdings in AbbVie were worth $7,000,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Zevin Asset Management LLC lifted its position in shares of AbbVie by 12.4% during the 2nd quarter. Zevin Asset Management LLC now owns 91,642 shares of the company’s stock valued at $17,011,000 after buying an additional 10,144 shares in the last quarter. Atlas Legacy Advisors LLC lifted its holdings in AbbVie by 21.7% during the second quarter. Atlas Legacy Advisors LLC now owns 1,282 shares of the company’s stock valued at $238,000 after purchasing an additional 229 shares in the last quarter. Savant Capital LLC grew its position in shares of AbbVie by 9.8% in the second quarter. Savant Capital LLC now owns 171,715 shares of the company’s stock valued at $31,874,000 after purchasing an additional 15,296 shares during the period. Texas Yale Capital Corp. grew its position in shares of AbbVie by 10.2% in the second quarter. Texas Yale Capital Corp. now owns 41,898 shares of the company’s stock valued at $7,777,000 after purchasing an additional 3,890 shares during the period. Finally, OneAscent Wealth Management LLC increased its stake in shares of AbbVie by 33.6% during the second quarter. OneAscent Wealth Management LLC now owns 2,434 shares of the company’s stock worth $452,000 after purchasing an additional 612 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ABBV. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. HSBC set a $225.00 price target on AbbVie in a research report on Thursday, October 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday. Finally, Morgan Stanley upped their target price on shares of AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $238.05.

AbbVie Stock Performance

NYSE ABBV opened at $219.13 on Friday. The company has a market cap of $387.11 billion, a P/E ratio of 104.35, a P/E/G ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The stock has a 50-day moving average of $223.06 and a two-hundred day moving average of $201.96.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the firm earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is presently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.